Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836880 in wAMD
NCT03861234Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2019
- Primary completion
- Nov 2023
- Modality
- Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 3
01
Overview
Phase 2, open-label trial of BI 836880 in exudative macular degeneration (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Participants With Ocular Dose Limiting Events (DLEs) up to 6 weeks and Number of Participants With Drug Related Adverse Events (AEs) up to 24 weeks. Started Jun 2019; status: completed.
02
Drugs
BI 836880
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03861234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861234.